Advanced analytical paradigms for cancer nanoparticles: integrative, translational, and regulatory-ready methodologies

Abstract

Cancer nanotechnology has developed into a tremendous and tough area of research that will require significant understanding and knowledge to be achieved. Currently, the high number of anti-cancer drugs in nanoparticle research still fail during animal or early stages of clinical studies. This is now becoming the trend due to the lack of the appropriate perspective despite the existence of the biological dynamic system that has governed the interaction of the nanomolecules in the body. This paper therefore differs from the norm since it is presenting an in-depth evaluation regarding the factors to consider during the research on the evaluation of cancer nanomolecules. By combining strategies about what nanoparticles are like, how they react with cell surfaces, what they do in cells, how they function in live biological systems, and how they are evaluated with quality checks, this paper develops a guessable strategy for evaluating them. Unlike other reviews, this one presents the analysis techniques as tools that can help improve formulas, reduce the chance of human failure, and get ready for a change in regulators’ perceptions of these novel treatments. The paper looks at recent trends and new patents to show how difficult this analysis can be. Future researchers who want to develop useful cancer nanoparticle platforms can use this work as a guide.